Next-Generation Technologies and Strategies for the Management of Retinoblastoma

Abstract

Retinoblastoma (RB) is an inherited retinal disorder (IRD) caused by the mutation in the RB1 gene or, rarely, by alterations in the MYCN gene. In recent years, new treatment advances have increased ocular and visual preservation in the developed world. The management of RB has improved significantly in recent decades, from the use of external beam radiation to recently, more localized treatments. Determining the underlying genetic cause of RB is critical for timely management decisions. The advent of next-generation sequencing technologies have assisted in understanding the molecular pathology of RB. Liquid biopsy of the aqueous humor has also had significant potential implications for tumor management. Currently, patients' genotypic information, along with RB phenotypic presentation, are considered carefully when making treatment decisions aimed at globe preservation. Advances in molecular testing that improve our understanding of the molecular pathology of RB, together with multiple directed treatment options, are critical for developing precision medicine strategies to treat this disease. Author Contributions: Conceptualization, J.L.B., S.J.T. and J.M.O.; investigation, H.V.G., J.L.B., A.P.; Data curation H.V.G., J.L.B., A.P.; writing-original draft preparation H.V.G., J.L.B.; writing-review and editing A.P., J.L.B., S.J.T. and J.M.O.; Visualization J.L.B. and J.M.O.; supervision, J.M.O.; funding acquisition, J.L.B. and J.M.O.

Downregulation of microRNA‑320a inhibits proliferation and induces apoptosis of retinoblastoma cells via targeting TUSC3

“…However, the aforementioned methods lack specificity, and exhibit destructive injuries, low safety, serious systemic and/or local adverse effects and other problems, such as tumor implantation and induction of secondary malignant tumors (2). With the development of tumor molecular biology and genetic engineering technology, coupled with the anatomical advantages of eyeballs as target tissues in the field of RB therapy, gene therapy, as a new type of biological therapy, has demonstrated good application prospects (3,4).…”

Long noncoding RNAs as potential biomarkers in retinoblastoma: a systematic review and meta-analysis

“…However, in developing countries, the situation is quite critical, probably due to rather high birth rates and limited medical resources. Approximately 40-70% of patients died in some Asian and African countries [4]. The largest hospital in South Western China used to conduct a retrospective study and found the majority of patients presented at advanced stage [5].…”

Ocular safety of repeated intravitreal injections of Carboplatin and Digoxin: A preclinical study on the healthy rabbits

“…Retinoblastoma is the most prevalent childhood primary intraocular malignant tumor with incidence of 1 per 15,000–20,000 live births. 1 Although systemic chemotherapy has become the cornerstone in the management of retinoblastoma 2 it is often tough to achieve complete tumor control in the presence of the vitreous seeds. 3 , 4 …”